Updated: 5 days ago
Medically reviewed by Dr. Wang
Key Takeaways |
|
Introduction
Recurrent stomach cancer treatment may include chemotherapy, targeted medicines, immunotherapy or a clinical trial, depending on where the cancer has returned, previous treatment and tumour test results. Hearing that the cancer is back does not tell you which option fits—or mean that nothing more can be done. The next useful step is to ask your oncologist how the current diagnosis, biomarkers and treatment history shape the plan.
Why Does Stomach Cancer Come Back?
Stomach cancer can return when cancer cells survive initial treatment and later grow enough to be detected. This does not automatically mean the original treatment was wrong or that the family caused the recurrence.
Recurrence may be near the original site, in nearby tissues or in distant parts of the body. Doctors reassess its extent using appropriate scans and, when needed, tissue testing. That assessment helps distinguish treatment of a limited recurrence from care for widespread disease.
This overview concerns gastric adenocarcinoma, the cancer type studied in the trials below. A gastrointestinal stromal tumour or lymphoma arising in the stomach follows a different pathway. Ask the team to confirm the exact pathology before comparing treatment names.
Table of Content
Which Tests Decide the Next Treatment for Recurrent Stomach Cancer Treatment?
The most useful discussion combines tumour biomarkers with a review of scans, pathology and previous medicines. Biomarkers are features of the cancer that can help identify relevant therapies; they do not replace an assessment of the person's health.
Test or assessment | What it helps decide | Question to ask |
HER2: human epidermal growth factor receptor 2 | Whether a HER2-directed pathway is relevant | Is the current cancer still HER2-positive, and would another biopsy help? |
MSI/MMR: microsatellite instability and mismatch repair | Whether MSI-high or mismatch repair-deficient disease supports an immunotherapy discussion | Have MSI or MMR results been documented? |
PD-L1: programmed death-ligand 1, reported as combined positive score (CPS) | Selection of certain checkpoint-inhibitor regimens | What is the actual CPS, and how does it affect this proposed regimen? |
CLDN18.2: claudin 18.2, assessed in tumour tissue | Whether a CLDN18.2-targeted pathway merits review | Which test and threshold does the proposed product require? |
Scans, blood tests, previous treatment and functional health | Disease extent, treatment timing and ability to tolerate a regimen | Which treatment line are we considering, and what limits the choices? |
Sources: NCI diagnosis and treatment information, Pan-Asian guidelines, FDA zolbetuximab indication and DESTINY-Gastric04.
Importantly, recurrence after surgery does not automatically mean second-line treatment for advanced disease. Someone who has not received systemic therapy for metastatic disease may be assessed for a first-line advanced-disease regimen; someone whose cancer progressed during such treatment has a different starting point. The oncologist must account for earlier perioperative medicines and the interval since treatment.
Option 1: Second-line Chemotherapy With Targeted Therapy
Ramucirumab plus paclitaxel is an established second-line option for appropriate patients whose advanced gastric cancer has progressed after initial systemic treatment. This pathway does not require a positive HER2 or CLDN18.2 result; the relevant checks include prior medicines, fitness and safety.
Paclitaxel is chemotherapy. Ramucirumab targets vascular endothelial growth factor receptor 2, a pathway involved in blood-vessel growth. The RAINBOW study supports the combination; its result appears in the evidence table below.
In later lines, trifluridine/tipiracil is another chemotherapy option supported by TAGS. An oral medicine still requires safety monitoring. Ask: “Which chemotherapy options remain reasonable after the medicines already used?”
Option 2: HER2-Targeted Treatment
A HER2-positive result can open a HER2-directed treatment discussion, but the medicine depends on prior therapy. For disease that progressed after trastuzumab-based treatment, trastuzumab deruxtecan is an important option to discuss.
Trastuzumab deruxtecan is an antibody-drug conjugate: a HER2-targeting antibody carries a cancer-killing drug. DESTINY-Gastric04 tested it against ramucirumab plus paclitaxel after progression on trastuzumab-based therapy, with HER2 positivity confirmed on a new tumour biopsy. Its survival result applies to that selected population, not to every person with recurrent stomach cancer.
Ask: “Does the latest tissue support this treatment, and how would you monitor lung toxicity?” Lung inflammation is a recognized risk of this medicine.
Option 3: Immunotherapy
Immunotherapy may be relevant when the biomarker profile and treatment setting support it. MSI-high or mismatch repair-deficient disease is particularly important to identify when discussing checkpoint inhibitors such as pembrolizumab.
PD-L1 CPS also guides some regimens, but it should not be treated as a universal permission for later-line immunotherapy. The specific drug combination, prior exposure and local indication still matter.
A newer regulatory example is the FDA's traditional approval of pembrolizumab with trastuzumab and chemotherapy for a defined first-line HER2-positive, PD-L1-positive population, summarized below. This is not evidence that the same combination is appropriate after it has already failed.
Ask: “Do MSI/MMR and PD-L1 results support immunotherapy now, and have we already used a checkpoint inhibitor?”
Option 4: CLDN18.2-Targeted Treatment, Including CAR-T
A CLDN18.2-positive result can prompt a targeted-treatment discussion, but zolbetuximab and satri-cel occupy different treatment settings. They are not interchangeable.
Zolbetuximab is an antibody used with chemotherapy. Its FDA indication is first-line treatment for qualifying HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma. It should not be presented as an established rescue treatment after several advanced-disease regimens have failed.
Satricabtagene autoleucel (satri-cel) is a chimeric antigen receptor T-cell therapy, or CAR-T, targeting CLDN18.2. A Chinese government report describes its approval for a defined later-line gastric/gastroesophageal junction population. The randomized CT041-ST-01 trial showed an improvement in progression-free survival against physician-selected treatment, as shown below.
Progression-free survival measures time before the cancer worsens or death occurs; it is different from overall survival. Neither endpoint establishes cure. A CLDN18.2 result must meet the relevant product's criteria, and international access requires separate confirmation.
What Did the Studies and Approvals Actually Show?
Evidence | Population and design | Verified finding | Meaning and limit |
RAINBOW, Lancet Oncology 2014 ; cross-checked in NCI | Randomized phase III; 665 patients with previously treated advanced gastric/GEJ adenocarcinoma | Median overall survival: 9.6 months with ramucirumab plus paclitaxel vs 7.4 months with placebo plus paclitaxel; HR 0.807 | Supports a second-line option; not an individual prognosis |
TAGS, Lancet Oncology 2018; cross-checked in NCI | Randomized phase III; 507 patients after at least two prior regimens | Median overall survival: 5.7 months with trifluridine/tipiracil vs 3.6 months with placebo; HR 0.69 | A later-line comparison; not comparable head-to-head with other trials |
DESTINY-Gastric04, NEJM 2025 | Randomized phase III; 494 patients, HER2-positive on biopsy after progression on trastuzumab-based therapy | Median overall survival: 14.7 vs 11.4 months for trastuzumab deruxtecan vs ramucirumab plus paclitaxel; HR 0.70, 95% CI 0.55–0.90 | Evidence for this HER2-selected population; lung toxicity remains relevant |
CT041-ST-01, Lancet 2025 | Randomized open-label phase II in China; 156 patients after at least two previous lines | Median progression-free survival: 3.25 months with satri-cel vs 1.77 months with physician's choice; HR 0.37, 95% CI 0.24–0.56 | Not an overall-survival comparison; follow-up for PFS was 9.07 vs 3.45 months |
CT041-ST-01 safety | Patients who received study treatment: 88 satri-cel, 48 comparator | Grade 3 or higher treatment-emergent adverse events: 99% vs 63%; cytokine release syndrome: 95% of satri-cel recipients | Serious toxicity and specialist monitoring are central to the discussion; not all treatment-emergent events are necessarily caused by the product |
Zolbetuximab FDA approval | Adults with CLDN18.2-positive, HER2-negative locally advanced unresectable or metastatic gastric/GEJ adenocarcinoma | Approved 18 October 2024 with fluoropyrimidine- and platinum-containing chemotherapy, first line | Biomarker positivity alone does not justify later-line use |
Pembrolizumab FDA approval | HER2-positive advanced gastric/GEJ disease, first line | Traditional approval 19 March 2025 with trastuzumab and chemotherapy; PD-L1 CPS ≥1 required | A defined combination and treatment setting |
Satri-cel Chinese approval reported by Pudong government | CLDN18.2-positive, HER2-negative unresectable advanced gastric/GEJ adenocarcinoma after progression on at least two lines | NMPA approval reported as 22 June 2026 | VERIFY the current regulator label before publication; government reporting is not full prescribing information |
Reading the table: Median means half the study participants experienced the endpoint earlier and half later. A hazard ratio below one favours the experimental group for that endpoint over follow-up; it is not the percentage of patients cured. These trials enrolled different populations and used different comparators, so their figures cannot rank the five options.
Option 5: Clinical Trials
Clinical trials may offer another route when standard treatment choices are limited or a suitable study fits the medical case. They have eligibility criteria and uncertain benefits; a registry entry does not guarantee an available place.
Ask for the trial registration number, current recruitment status, participating site, required biomarkers, allowed previous treatments and expected visits. Discuss how screening fits with care needed now. The published CT041-ST-01 report states that its trial was closed to new patients; its results should not be advertised as an open recruitment offer.
For families in Southeast Asia, Australia and New Zealand, ask separately about local authorization, funding and insurance. A US or Chinese approval does not establish approval or reimbursement in your home country.
What Are the Risks, and When Should We Talk to Our Doctor?
Discuss benefits, side effects and the purpose of treatment before choosing a regimen. Chemotherapy can lower blood counts and increase infection or bleeding risk. Checkpoint inhibitors can inflame healthy organs. Trastuzumab deruxtecan can cause lung inflammation; CAR-T can cause cytokine release syndrome and substantial blood-count suppression.
Risks and Side Effects
Ask for a written plan covering common side effects, serious warning signs, blood tests and whom to contact after hours. Include nutrition, pain control and supportive care in the discussion; these needs remain important alongside anticancer treatment.
When to Contact Your Doctor
Contact the team promptly for fever during treatment, new cough or breathlessness, severe diarrhoea, confusion, or bleeding such as vomiting blood or black stools. Follow the team's emergency instructions; severe breathing problems or major bleeding need urgent medical assessment. Do not wait for the next routine consultation.
Get a Second Opinion Before Fly to China
For suitable cases, ChinaCureLink can then coordinate an online consultation with the specialist to discuss the technical treatment details directly. The purpose is to help the patient understand which treatment option and which specialist center may be most appropriate before making an international treatment decision.
What Patients Say About ChinaCureLink & Medebound HEALTH
China CureLink operates under Medebound HEALTH — an internationally recognized healthcare navigation company incorporated in New York, with operations across North America and Asia-Pacific.
Frequently Asked Questions
What Is the Survival Rate for Recurrent Stomach Cancer?
There is no single survival rate that describes every recurrence. Where the cancer has returned, tumour biology, previous treatment and current health affect the outlook. The table reports outcomes from selected trial populations, not a personal prediction; ask your oncologist for an estimate relevant to your case and treatment goals.
Can Recurrent Stomach Cancer Be Treated?
Yes. Depending on the medical case, treatment may include chemotherapy, targeted medicines, immunotherapy or a clinical trial. For widespread disease, treatment often aims to control cancer and symptoms rather than cure it. A suitable plan depends on the cancer's extent, previous medicines, biomarkers and current health.
What Tests Should I Ask for if Stomach Cancer Comes Back?
Ask about confirmation of recurrence and updated staging, plus HER2, MSI/MMR, PD-L1 CPS and CLDN18.2 testing when relevant to available treatment pathways. Ask whether existing tissue is adequate or a new biopsy would help. Blood tests and a review of previous medicines and current health are also important; no test result alone establishes eligibility.
About ChinaCureLink
ChinaCureLink helps patients across the world access the best cancer treatment at China's top hospitals, without the delays, language barriers, and administrative confusion that typically come with seeking care abroad.
We connect patients directly with China's top cancer hospitals, ensuring that from the first case submission through to treatment and follow-up, every step is guided, translated, and coordinated by a team experienced in cross-border patient care.
ChinaCureLink is proudly affiliated with Medebound HEALTH — founded by US physicians, with over 10 years of experience and more than 3,000 patients served worldwide, Medebound HEALTH is recognized by Forbes and it is one of the most trusted patient cross-border concierge service company across North America and the Asia Pacific.
Disclaimer
This article is for informational purposes only and is not medical or financial advice. Treatment eligibility, protocols, and costs vary by individual case — confirm specifics with a coordinator and treating physician before making any decisions.
Sources
National Cancer Institute. Recurrent Cancer: When Cancer Comes Back. Updated 2 April 2025. https://www.cancer.gov/types/recurrent-cancer
National Cancer Institute, PDQ Adult Treatment Editorial Board. Gastric Cancer Treatment (PDQ), Health Professional Version. Updated 21 February 2025. https://www.cancer.gov/types/stomach/hp/stomach-treatment-pdq
Shitara K et al. Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with gastric cancer. ESMO Open. Published online 3 February 2024;9:102226. https://pmc.ncbi.nlm.nih.gov/articles/PMC10937212/
National Cancer Institute. Stomach Cancer Diagnosis and Tests. Updated 31 May 2023. https://www.cancer.gov/types/stomach/diagnosis
Shitara K et al. Trastuzumab Deruxtecan or Ramucirumab plus Paclitaxel in Gastric Cancer. NEJM. Published online 31 May 2025; issue 24 July 2025;393:336–348. DOI 10.1056/NEJMoa2503119. https://pubmed.ncbi.nlm.nih.gov/40454632/
FDA. FDA approves pembrolizumab for HER2 positive gastric or gastroesophageal junction adenocarcinoma expressing PD-L1 (CPS ≥1). 19 March 2025. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pembrolizumab-her2-positive-gastric-or-gastroesophageal-junction-adenocarcinoma
FDA. FDA approves zolbetuximab-clzb with chemotherapy for gastric or gastroesophageal junction adenocarcinoma. 18 October 2024. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-zolbetuximab-clzb-chemotherapy-gastric-or-gastroesophageal-junction-adenocarcinoma
Shanghai Pudong New Area Government. Pudong company's world-first solid tumor CAR-T therapy approved in China. 24 June 2026. https://english.pudong.gov.cn/2026-06/24/c_1192878.htm
Wilke H et al. RAINBOW. Lancet Oncology. November 2014;15:1224–1235. Trial citation and results cross-checked in source 2. https://pubmed.ncbi.nlm.nih.gov/25240821/
Shitara K et al. TAGS. Lancet Oncology. November 2018;19:1437–1448. Trial citation and results cross-checked in source 2. https://pubmed.ncbi.nlm.nih.gov/30355453/
Qi C et al. CT041-ST-01: a randomised, open-label, phase 2 trial. Lancet. Published online 31 May 2025; issue 7 June 2025;405:2049–2060. DOI 10.1016/S0140-6736(25)00860-8. https://pubmed.ncbi.nlm.nih.gov/40460847/
National Cancer Institute. Steps to Find a Clinical Trial. Update date not recorded in retrieved content. https://www.cancer.gov/research/participate/clinical-trials-search/steps
National Cancer Institute. Organ-Related Inflammation and Immunotherapy. Posted 14 June 2019. https://www.cancer.gov/about-cancer/treatment/side-effects/organ-inflammation
National Cancer Institute. Infection and Neutropenia and Cancer Treatment. Reviewed 23 January 2020. https://www.cancer.gov/about-cancer/treatment/side-effects/infection
National Cancer Institute. Bleeding and Bruising and Cancer Treatment. Reviewed 29 December 2022. https://www.cancer.gov/about-cancer/treatment/side-effects/bleeding-bruising
National Cancer Institute. Stomach Cancer Treatment by Stage. Updated 10 April 2025. https://www.cancer.gov/types/stomach/treatment/by-stage
